Caris Life Sciences Stock Forecast
NASDAQ: CAIHealth CareMedical SpecialitiesUSD
Market open · Delayed 15 min · as of Oct 9, 12:13 PM ET
CAI analyst consensus
Consensus (14 analysts)
buy
Avg. price target
$29.08-0.02%
- Strong buy 1
- Buy 9
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 14 Wall Street analysts covering Caris Life Sciences (2026-10-07), 10 rate the stock a buy or strong buy, 4 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $29.08, with a high estimate of $38.00 and a low estimate of $22.00. The average target implies downside of 0.0% from the current price of $29.09.
The spread between the highest and lowest targets is 72.7%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CAI.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 7% |
| Buy | 9 | 64% |
| Hold | 4 | 29% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $22.00 | -24.36% |
| Average target | $29.08 | -0.02% |
| High target | $38.00 | +30.65% |